KesselADKlineMZingerMMcLaughlinDSilverPSwebergTM. The impact and statistical analysis of a multifaceted anticoagulation strategy in children supported on ECMO: performance and pitfalls. J Intensive Care Med. 2017;32(1):59–67.
2.
StockerCFHortonSB. Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO). Perfusion. 2016;31(2):95–102.
3.
WerhoDKPasqualiSKYuS. Hemorrhagic complications in pediatric cardiac patients on extracorporeal membrane oxygenation: an analysis of the Extracorporeal Life Support Organization Registry. Pediatr Crit Care Med. 2015;16(3):276–288.
4.
YieKChonSHNaCY. Activated clotting time test alone is inadequate to optimize therapeutic heparin dosage adjustment during post-cardiopulmonary resuscitational extracorporeal membrane oxygenation (e-CPR). Perfusion. 2016;31(4):307–315.
5.
CunninghamDBesserMWGiraudKGerrardCVuylstekeA. Agreement between ACT and aPTT during extracorporeal membrane oxygenation shows intra- and inter-individual variation. Perfusion. 2016;31(6):503–507.
6.
AtallahSLieblMFitousisKBostanFMasudF. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion. 2014;29(5):456–461.
7.
ChuDCAbu-SamraAGBairdGL. Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation. Intensive Care Med. 2015;41(2):369–370.
8.
FitousisKKlasekRMasonPMasudF. Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients. Perfusion. 2017;32(3):238–244.
9.
O’MearaLCAltenJAGoldbergKG. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. ASAIO J. 2015;61(3):339–344.
10.
StansfieldBKWiseLHamPB3rd. Outcomes following routine antithrombin III replacement during neonatal extracorporeal membrane oxygenation. J Pediatr Surg. 2017;52(4):609–613.
11.
RyersonLMBruceAKLequierLKuhleSMassicotteMPBaumanME. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. ASAIO J. 2014;60(5):559–563.
12.
NorthropMSSidonioRFPhillipsSE. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med. 2015;16(1):66–74.
13.
LimJYKimJBChooSJChungCHLeeJWJungSH. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg. 2016;102(2):534–539.
14.
LathamGJJefferis KirkCFalconerADickeyRAlbersELMcMullanDM. Challenging argatroban management of a child on extracorporeal support and subsequent heart transplant. Semin Cardiothorac Vasc Anesth. 2016;20(2):168–174.
15.
RanucciMBallottaAKandilH. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15(6): R275.
